Drug Profile
HL 186
Alternative Names: HL-186Latest Information Update: 29 Oct 2021
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Oct 2021 Preclinical trials in Cancer in South Korea, before October 2021 (Parenteral)
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
- 24 Jul 2017 Early research in Cancer in South Korea (Parenteral) (HanAll Biopharma pipeline, July 2017)